grazoprevir

has antiviral activity; component of Zepatier

Also Known As:

MK 5172; MK-5172; MK-5172 monohydrate; MK5172; cyclopropanecarboxamide, N-((((1R,2R)-2-(5-(3-hydroxy-6-methoxy-2-quinoxalinyl)pentyl)cyclopropyl)oxy)carbonyl)-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-, cyclic (1->2)-ether, hydrate (1 :1) (1R,2S)-; cyclopropanecarboxamide, n-((((1r,2r)-2-(5-(3-hydroxy-6-methoxy-2-quinoxalinyl)pentyl)cyclopropyl)oxy)carbonyl)-3-methyl-l-valyl-(4R)-4-hydroxy-l-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-, cyclic (1->2)-ether, (1R,2S)-; grazoprevir anhydrous; grazoprevir hydrate; grazoprevir monohydrate

Networked: 202 relevant articles (56 outcomes, 70 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Barr, Eliav: 26 articles (01/2019 - 03/2015)
2.	Wahl, Janice: 25 articles (05/2018 - 08/2014)
3.	Hwang, Peggy: 23 articles (12/2020 - 08/2014)
4.	Robertson, Michael N: 20 articles (12/2020 - 08/2014)
5.	Robertson, Michael: 16 articles (01/2019 - 03/2015)
6.	Talwani, Rohit: 13 articles (12/2020 - 01/2017)
7.	Asante-Appiah, Ernest: 11 articles (12/2020 - 01/2016)
8.	Caro, Luzelena: 11 articles (09/2019 - 08/2014)
9.	Haber, Barbara: 10 articles (12/2019 - 03/2015)
10.	Butterton, Joan R: 9 articles (05/2019 - 07/2015)

Related Diseases

1.	Infections 01/01/2018 - "The aim of this long-term observational study was to evaluate the persistence of NS3/4A and NS5A RASs in participants with genotype (GT) 1 infection who relapsed following treatment with a grazoprevir-containing treatment regimen. " 02/01/2016 - "In this randomized, dose-ranging, multicentre trial, treatment-naive adults with chronic HCV genotype 1 infection received once-daily grazoprevir 25 mg, 50 mg or 100 mg plus PEG-IFN/RBV for 12 weeks. " 12/15/2014 - "Six of 266 (2.3%) MK-5172 recipients satisfied prespecified criteria for virologic failure, all with genotype 1a infection. " 01/01/2018 - "Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection." 08/01/2014 - "Once-daily MK-5172 (100 mg) with PR for 24 or 48 weeks was highly effective and well tolerated among treatment-naive patients with HCV genotype 1 infection without cirrhosis. "
2.	Fibrosis (Cirrhosis) 01/01/2019 - "In this 12-week, phase 2, nonrandomized, open-label study (NCT02115321; Protocol MK-5172-059), participants with CP-B cirrhosis received EBR 50 mg plus GZR 50 mg once daily, and a control group of noncirrhotic participants received EBR 50 mg plus GZR 100 mg once daily. " 08/01/2014 - "Once-daily MK-5172 (100 mg) with PR for 24 or 48 weeks was highly effective and well tolerated among treatment-naive patients with HCV genotype 1 infection without cirrhosis. " 01/01/2019 - "Conclusion: Grazoprevir/elbasvir was effective in genotype 1 patients co-infected with HIV with or without cirrhosis. " 01/01/2020 - "Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis." 01/01/2020 - "Accordingly, we evaluated the efficacy of 8 weeks fixed-dose combination of grazoprevir-elbasvir in treatment-naïve patients, with non-severe fibrosis. "
3.	Hepatitis C 06/01/2016 - "Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C." 01/01/2019 - "Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial." 01/01/2021 - "Here, we investigated the adherence to these recommendations and the effectiveness of elbasvir/grazoprevir in a large German Hepatitis C-Registry GT1a cohort. " 01/01/2021 - "Elbasvir and grazoprevir for the treatment of hepatitis C." 10/01/2016 - "C-WORTHY: the beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients."
4.	Chronic Hepatitis C 01/01/2018 - "Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence." 01/01/2023 - "An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir-grazoprevir treatment association for chronic hepatitis C in France (ZEPHYR study)." 01/01/2022 - "This study aims to systematically review recent economic evaluations of elbasvir/grazoprevir (EBR/GZR) for chronic hepatitis C (CHC), to critically appraise the reporting quality and to summarize the results. " 01/01/2020 - "The Z-Profile Study: a multicenter, retrospective cohort study to assess the real-world use and effectiveness of elbasvir/grazoprevir in Canadian adult patients with chronic hepatitis C." 01/01/2022 - "Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review."
5.	Kidney Diseases (Kidney Disease) 01/01/2018 - "Editorial: real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease." 01/01/2018 - "Editorial: real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease-Author's reply." 01/01/2018 - "In this issue, Alric and colleagues demonstrate through real-world experience that grazoprevir-elbasvir is safe and effective for treating hepatitis C in advanced kidney disease patients with higher comorbidity burdens. " 06/01/2017 - "While safety and efficacy with sofosbuvir remains uncertain, data are now available to support utilizing a dose adjustment when glomerular filtration rates are <30 mL/min. Upcoming regimens grazoprevir/elbasvir and daclatasvir/asunaprevir/beclavubir may provide further options for patients with advanced kidney disease, and ongoing studies will continue to provide guidance for this unique patient population. " 12/01/2022 - "Abbreviations: DAA: direct-acting antivirals; HCV: hepatitis C virus; NAT: nucleic acid testing; OPTN: Organ Procurement and Transplantation Network; KDIGO: Kidney Disease: Improving Global Outcomes; Ab: antigen; eGFR: estimated glomerular filtration rate; D: donor; R: recipient; CMV: cytomegalovirus; HBV: hepatitis B virus; UNOS: United Network for Organ Sharing; PHS: Public Health Service; EBR/GZR: elbasvir/grazoprevir; SVR: sustained virologic response; RAS: resistance-associated substitutions; SOF: soforbuvir; GLE/PIB: glecaprevir/pibrentasvir; ACR: acute cellular rejection; AR: acute rejection; DSA: donor-specific antibodies; KTR: kidney transplant recipients; AASLD: American Association for the Study of Liver Disease; IDSA: Infectious Diseases Society of America; PPI: proton pump inhibitors; CKD: chronic kidney disease; GN: glomerulonephritis; KAS: The Kidney Allocation system."

Related Drugs and Biologics

1.	elbasvir
2.	Ribavirin (Virazole)
3.	Sofosbuvir
4.	daclatasvir
5.	Interferons
6.	uprifosbuvir
7.	ruzasvir
8.	Antiviral Agents (Antivirals)
9.	sofosbuvir drug combination ledipasvir
10.	asunaprevir

Related Therapies and Procedures

1.	Therapeutics
2.	Renal Dialysis (Hemodialysis)
3.	Retreatment
4.	Liver Transplantation
5.	Aftercare (After-Treatment)

HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Application Error

An application error has occurred and our support engineers have been notified.

Please use the browser "Back" button and try your operation again.

OR if the error persists and you require an email response
please contact us at "cs at curehunter.com":

Your request
The circumstances of the error
Your login id/nickname or email

Return to Top Page